Cultivated bluefin tuna reported 'weeks' from FDA clearance - but BlueNalu has none on record as of 7 Jul 2026

Why it matters (money + metacrisis). Cultivated seafood aims at high-value, supply-constrained species — bluefin toro commands premium sushi prices while wild bluefin stocks are heavily fished — so a cleared cultivated toro is a genuine money story and an overfishing-relief (ocean / food-security) lever. The pathway is proven: Wildtype's cell-cultivated salmon received an FDA no-questions letter on 28 May 2025, the first cultivated seafood cleared for US sale. The open question is whether BlueNalu has actually crossed the same line — and right now the public record says it has not.

What would prove it wrong (either way). A completed FDA pre-market consultation or posted record for BlueNalu would confirm clearance and upgrade this to verified; continued absence confirms the caution. The falsifier for the bullish "already/imminently cleared" narrative is simply the FDA record staying empty.

Live-status check (2026-07-07). At Seafood Expo North America (March 2026), trade coverage (SeafoodSource) reported BlueNalu expected an FDA no-questions finding "within weeks" and planned a San Diego restaurant debut. As of this check, BlueNalu's own newsroom (bluenalu.com/press-releases) shows no clearance announcement — its most recent release is a 29 Dec 2025 financing — and no completed FDA consultation for BlueNalu is on the public record. The company is clearly still operating (Dec 2025 raise), so this is "not yet," not "defunct." Treat "cleared/imminent" as an unverified forward claim. Primary: BlueNalu newsroom (first-party); the trade-press "weeks away" line is signal only, never a source of record.